Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLH | Q9Y253 | 5/20 | 0.80 |
| ▸ | MEN1 | O00255 | 8/20 | 0.74 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.74 |
| ▸ | CYP3A4 | P08684 | 7/20 | 0.74 |
| ▸ | ABCB1 | P08183 | 7/20 | 0.74 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.74 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.74 |
| ▸ | FTO | Q9C0B1 | 5/20 | 0.74 |
| ▸ | CYP1A2 | P05177 | 5/20 | 0.74 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.74 |
| ▸ | MAPT | P10636 | 5/20 | 0.74 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.74 |
| ▸ | CYP1A1 | P04798 | 4/20 | 0.74 |
| ▸ | CYP1B1 | Q16678 | 4/20 | 0.74 |
| ▸ | XDH | P47989 | 4/20 | 0.74 |
| ▸ | TP53 | P04637 | 4/20 | 0.74 |
| ▸ | ALOX15 | P16050 | 4/20 | 0.74 |
| ▸ | APP | P05067 | 4/20 | 0.74 |
| ▸ | CA12 | O43570 | 3/20 | 0.74 |
| ▸ | BCHE | P06276 | 3/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30819258 | 1.00 | POLH (0.80) | POLHMEN1KMT2ACYP3A4ABCB1 | |
| SCHEMBL9733297 | 0.90 | ABCB1 (0.76) | POLHMEN1KMT2ACYP3A4ABCB1 | |
| SCHEMBL9565912 | 0.90 | POLH (0.65) | POLHMEN1KMT2ACYP3A4ABCB1 | |
| SCHEMBL12636895 | 0.90 | CYP3A4 (0.74) | POLHMEN1KMT2ACYP3A4ABCB1 | |
| SCHEMBL824468 | 0.89 | POLH (1.00) | POLHMEN1KMT2ACYP3A4ABCB1 | |
| SCHEMBL13776268 | 0.87 | POLH (0.82) | POLHMEN1KMT2ACYP3A4ABCB1 | |
| SCHEMBL13056253 | 0.87 | POLH (0.78) | POLHMEN1KMT2ACYP3A4ABCB1 | |
| SCHEMBL16682483 | 0.87 | POLH (0.77) | POLHMEN1KMT2ACYP3A4ABCB1 | |
| SCHEMBL14004949 | 0.85 | MAPT (0.76) | POLHMEN1KMT2ACYP3A4ABCB1 | |
| SCHEMBL13552041 | 0.85 | MEN1 (0.76) | POLHMEN1KMT2ACYP3A4ABCB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4243809-A2 | COMPOUNDS AND METHODS FOR TREATING VIRAL INFECTIONS | Beth Israel Deaconess Medical Center, Inc. (US) | 2023-09-20 | — | — | EP | claimed |
| WO-2022104153-A2 | COMPOUNDS AND METHODS FOR TREATING VIRAL INFECTIONS | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2022-05-19 | — | — | WO | claimed |
| CN-117740961-A | Compound analysis method of liquorice and liquorice probiotics fermentation preparation | 北京中医药大学 | 2024-03-22 | — | — | CN | disclosed |
| US-20240016777-A1 | COMPOUNDS AND METHODS FOR TREATING VIRAL INFECTIONS | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 2024-01-18 | — | — | US | disclosed |
| US-20230041523-A1 | COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE AND METABOLIC DISORDERS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED | 2023-02-09 | — | — | US | disclosed |
| US-8541383-B2 | Synergistic phytochemical composition for the treatment of obesity | Laila Nutraceurticals (IN) | 2013-09-24 | — | — | US | disclosed |
| US-8450377-B2 | 1-adamantyl chalcones for the treatment of proliferative disorders | ANDERSON GLORIA L (US) | 2013-05-28 | — | — | US | disclosed |
| US-8450377-B2 | 1-adamantyl chalcones for the treatment of proliferative disorders | ANDERSON GLORIA L (US) | 2013-05-28 | — | — | US | disclosed |
| US-20110319483-A1 | 1-ADAMANTYL CHALCONES FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | ANDERSON GLORIA L (US) | 2011-12-29 | — | — | US | disclosed |
| US-20110319483-A1 | 1-ADAMANTYL CHALCONES FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | ANDERSON GLORIA L (US) | 2011-12-29 | — | — | US | disclosed |
| US-8013020-B2 | 1-adamantyl chalcones for the treatment of proliferative disorders | Anderson et al., Gloria L. (US) | 2011-09-06 | — | — | US | disclosed |
| US-7880059-B2 | Production of proanthocyanidins to improve forage quality | THE SAMUEL ROBERTS NOBLE FOUNDATION (US) | 2011-02-01 | — | — | US | disclosed |
| US-20100227828-A1 | NEW SYNERGISTIC PHYTOCHEMICAL COMPOSITION FOR THE TREATMENT OF OBESITY | LAILA NUTRACEUTICALS (IN) | 2010-09-09 | — | — | US | disclosed |
| US-20090281196-A1 | 1-ADAMANTYL CHALCONES FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | ANDERSON GLORIA L | 2009-11-12 | — | — | US | disclosed |
| US-20090281196-A1 | 1-ADAMANTYL CHALCONES FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | ANDERSON GLORIA L | 2009-11-12 | — | — | US | disclosed |
| US-7563789-B2 | 1-Adamantyl chalcones for the treatment of proliferative disorders | ANDERSON GLORIA LONG | 2009-07-21 | — | — | US | disclosed |
| US-7563789-B2 | 1-Adamantyl chalcones for the treatment of proliferative disorders | ANDERSON GLORIA LONG | 2009-07-21 | — | — | US | disclosed |
| US-20090083874-A1 | PRODUCTION OF PROANTHOCYANIDINS TO IMPROVE FORAGE QUALITY | THE SAMUEL ROBERTS NOBLE FOUNDATION | 2009-03-26 | — | — | US | disclosed |
| EP-1503771-A1 | SEDATIVE MATERIALS AND TREATMENTS | UNIVERSITY OF STRATHCLYDE (GB) | 2005-02-09 | — | — | EP | disclosed |
| WO-2003061678-A1 | SEDATIVE MATERIALS AND TREATMENTS | UNIVERSTIY OF STRATHCLYDE (GB) | 2003-07-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090083874-A1 | PRODUCTION OF PROANTHOCYANIDINS TO IMPROVE FORAGE QUALITY | QPCTL, FABP6, HHAT | POLH 2017/4885MEN1 2562/4885KMT2A 2296/4885 |
| US-20230041523-A1 | COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE AND METABOLIC DISORDERS | NLN, GLS, PRNP | POLH 4239/4885MEN1 3772/4885KMT2A 3429/4885 |
| US-20090281196-A1 | 1-ADAMANTYL CHALCONES FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | BRCA1, CYP19A1, HSD17B11 | POLH 332/4885MEN1 143/4885KMT2A 4038/4885 |
| US-20100227828-A1 | NEW SYNERGISTIC PHYTOCHEMICAL COMPOSITION FOR THE TREATMENT OF OBESITY | BMI1, FABP4, LIPC | POLH 2963/4885MEN1 3040/4885KMT2A 63/4885 |
| US-20240016777-A1 | COMPOUNDS AND METHODS FOR TREATING VIRAL INFECTIONS | THPO, SERPINB1, SERPINC1 | POLH 1533/4885MEN1 740/4885KMT2A 4220/4885 |
| US-20110319483-A1 | 1-ADAMANTYL CHALCONES FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | BRCA1, CYP19A1, HSD17B11 | POLH 332/4885MEN1 143/4885KMT2A 4038/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.